Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

• Published in: Arthritis research & therapy Vol. 21; no. 1; pp. 229 - 9
• Main Authors: Rey, Amayelle, Batteux, Benjamin, Laville, Solène M, Marienne, Justine, Masmoudi, Kamel, Gras-Champel, Valérie, Liabeuf, Sophie
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.11.2019; BMC; BioMed Central
• Subjects: Acute kidney failure; Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Acute renal failure; Adult; Aged; Allopurinol - adverse effects; Case studies; Drugs; Febuxostat; Febuxostat - adverse effects; Female; Gout; Gout - drug therapy; Gout - epidemiology; Gout suppressants; Gout Suppressants - adverse effects; Humans; Kidney failure; Kidney stones; Life Sciences; Male; Marketing; Middle Aged; Pharmacovigilance; Physicians; Post-marketing study; Prescription writing; Product Surveillance, Postmarketing - methods; Product Surveillance, Postmarketing - trends; Treatment Outcome; Urate-lowering therapies; Post-marketing study; Urate-lowering therapies; Pharmacovigilance; Acute renal failure
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-019-2011-y

For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment. Due to the widespread use of these ULTs (especially in patients with impaired renal function), assessment of the associated renal risk is essential. Accordingly, we performed a disproportionality analysis of reported cases of acute renal failure (ARF) associated with allopurinol and febuxostat. We carried out a case/non-case study of the World Health Organization's VigiBase® pharmacovigilance database between January 1, 2008, and December 31, 2018. The frequency of reports of ARF as a standardized Medical Dictionary for Regulatory Activities query for allopurinol and febuxostat was compared with that of all other reports for the two drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. The results' stability was assessed in a series of sensitivity analyses (notably after the exclusion of putative competing drugs). Among 3509 "suspected drug" notifications for febuxostat and 18,730 for allopurinol, we identified respectively 317 and 1008 cases of ARF. Acute renal failure was reported significantly more frequently for febuxostat and allopurinol than for other drugs (ROR [95%CI] 5.67 [5.05-6.36] and 3.25 [3.05-3.47], respectively). For both drugs, the ROR was higher in women than in men, respectively 11.60 [9.74-13.82] vs. 3.14 [2.69-3.67] for febuxostat and 4.45 [4.04-4.91] vs. 2.29 [2.11-2.50] for allopurinol. The sensitivity analyses confirmed the disproportionality for these two ULTs. Acute renal failure was reported respectively 5.7 and 3.3 times more frequently for febuxostat and for allopurinol than for other drugs. Due to the potential consequences of ARF, physicians should take account of this disproportionality signal when prescribing the ULTs febuxostat and allopurinol.